Biocon Limited has announced its audited financial results for the year ended March 31, 2026, reporting a consolidated annual revenue of Rs. 1,69,270 million. The company’s board has recommended a final dividend of Re. 0.50 per share. Additionally, Biocon revealed a strategic plan to fully integrate Biocon Biologics Limited (BBL) as a wholly owned subsidiary through a share swap mechanism to create a unified global biopharmaceutical leader.
Financial Performance Overview
For the financial year ended March 31, 2026, Biocon achieved consolidated revenue of Rs. 1,69,270 million, compared to Rs. 1,52,617 million in the previous year. The consolidated net profit for the year stood at Rs. 3,688 million. On a standalone basis, the company reported annual revenue of Rs. 23,464 million with a net profit of Rs. 372 million.
Dividend Recommendation
The Board of Directors has recommended a final dividend of 10%, amounting to Re. 0.50 per equity share (face value of Rs. 5) for the financial year ended March 31, 2026. The record date for determining shareholder entitlement is July 03, 2026, with the payout scheduled on or before August 31, 2026, subject to approval at the upcoming Annual General Meeting.
Strategic Integration of Biocon Biologics
Biocon has entered a phase of full integration with its material subsidiary, Biocon Biologics Limited (BBL). To streamline this transition and establish BBL as a wholly owned subsidiary, the company has approved the acquisition of remaining equity shares from employees and other shareholders through a share swap. This Preferential Issue involves the issuance of up to 87,92,317 equity shares of Biocon at an issue price of Rs. 376.16 per share.
Governance and Leadership Changes
The company announced several key leadership and board appointments to support its growth strategy:
- Statutory Auditors: M/s. S. R. Batliboi & Associates LLP have been recommended for appointment for a five-year term (2026-2031).
- Senior Management: Dr. Anuj Goel (Chief Development Officer) and Mr. Susheel Umesh (Chief Commercial Officer – Emerging Markets) have been designated as Senior Management Personnel.
- Board Appointments: Several new Independent Directors, including Mr. Rajiv Malik, Mr. Daniel Bradbury, Mr. Peter Baron Piot, Mr. Arun Suresh Chandavarkar, and Ms. Nivruti Rai, have been recommended for appointment effective August 01, 2026.
Long-Term Incentive Plans
To align the interests of its workforce with organizational growth, the Board has approved the Biocon Unity Long Term Incentive Plan 2026. This initiative includes various stock-based incentives and purchase plans for eligible employees of the company and its subsidiaries.
Source: BSE
